Related Experiment Video

Updated: Jul 20, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.2K

Non-coding RNA-directed therapeutics in lung cancer: Delivery technologies and clinical applications

Ahmed A H Abdellatif1, Giulia Scagnetti2, Mahmoud A Younis3

  • 1Department of Pharmaceutics, College of Pharmacy, Qassim University, Al Qassim 51452, Saudi Arabia; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.

Colloids and Surfaces. B, Biointerfaces
|July 29, 2023
PubMed

Insights

Targeting non-coding RNA (ncRNA) shows promise for lung cancer treatment. This review explores ncRNA therapy delivery methods and challenges, highlighting advanced technologies for clinical application.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Lung cancer remains a leading cause of mortality, necessitating novel therapeutic strategies.
  • Non-coding RNAs (ncRNAs) play crucial roles in cancer development and progression.
  • Current ncRNA-directed therapies face significant delivery challenges to reach lung cancer cells effectively.

Purpose of the Study:

  • To provide an overview of ncRNA's therapeutic potential in lung cancer treatment.
  • To discuss current challenges and innovative approaches for delivering ncRNA therapies to lung cancer cells.
  • To explore limitations in clinical trials and suggest future directions for ncRNA-based lung cancer therapies.

Main Methods:

  • Review of recent literature on ncRNA therapeutics for lung cancer.
  • Analysis of advanced delivery technologies, including chemically-modified oligonucleotides and nuclear targeting.
  • Examination of non-viral delivery systems such as nanoparticles, biomimetic systems, and extracellular vesicles.
  • Discussion of three-dimensional in vitro models for therapeutic assessment.

Main Results:

  • ncRNA targeting presents a promising avenue for lung cancer treatment.
  • Various advanced chemical modifications and delivery systems enhance ncRNA therapy efficacy.
  • Novel non-viral vectors and in vitro models are improving therapeutic delivery and evaluation.

Conclusions:

  • Overcoming delivery obstacles is critical for advancing ncRNA therapies in lung cancer.
  • Continued innovation in delivery systems and clinical trial design is essential for therapeutic success.
  • Targeting ncRNAs offers a significant future direction for effective lung cancer treatment.
Keywords:
Lung cancerNanocarriersNon-coding RNAOligonucleotides

More Related Videos

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Regulated mRNA Transport02:22

Regulated mRNA Transport

2.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
54